Some Antidepressants Sustain Better Long-Term Relief

Adults with major depression may find certain drugs keep symptoms improved longer than fluoxetine, according to a 115-study review.

Updated on Nov. 11, 2026 in Mental Health

Smooth unmarked capsules and tablets rest on a pale stone surface beside a clear glass of water in soft daylight.
A meta-analysis of 115 studies found escitalopram, duloxetine and agomelatine kept depression symptoms improved longer than fluoxetine, or Prozac. AI Illustration. Upload story photo >

Live Poll

Would you trust a doctor's antidepressant choice based on long-term research?

A meta-analysis of 115 studies covering 21 antidepressants found that most performed comparably to fluoxetine (Prozac) over the long term, while escitalopram (Lexapro), duloxetine (Cymbalta) and agomelatine (Thymanax) showed greater sustained symptom improvement. The study, published in The Lancet Psychiatry, pooled published and unpublished trials of adults with major depressive disorder.

Why it matters

Most antidepressant trials run about eight weeks, so little evidence has shown how these drugs compare over the months and years many people actually use them. Because this analysis tracked participants who stopped a drug for any reason as not improved, it reflects what patients experience in practice, not only the results of completed trials.

This meta-analysis pooled 115 studies of participants with major depressive disorder lasting more than 12 weeks, with one lasting up to two years. It compared each of 21 antidepressants with fluoxetine on sustained response, defined as symptom improvement lasting until the trial ended, and counted participants who discontinued for any reason as not improved.

The players

The Lancet Psychiatry

A peer-reviewed medical journal that publishes research on mental health and psychiatric treatment.

Fluoxetine (Prozac)

A widely prescribed selective serotonin reuptake inhibitor used as the reference drug for comparison in this analysis.

The details

Researchers combined published and unpublished studies and measured two outcomes: whether participants kept an improvement until the trial ended, and whether they stopped taking the drug. Because stopping counted against a drug, a medication that was hard to stay on scored lower even if it worked well when taken. This approach reflects the real-world challenge of sustaining treatment over time rather than only short-term response.

Timeline

  1. Most antidepressant trials prior to this analysis lasted around eight weeks.

  2. The meta-analysis was published in The Lancet Psychiatry on November 10, 2026.

Health Landscape

Most antidepressant evidence has come from trials lasting about eight weeks, leaving the comparative long-term performance of these drugs largely unmeasured. This analysis begins to fill that gap by examining sustained response across studies lasting months to years.

If you take or are considering an antidepressant, the findings suggest that sustaining improvement over time may differ between medications, so it is worth discussing long-term goals with your doctor. Do not start, stop or change any medication based on this study alone; the decision belongs with your prescriber.

The takeaway

Longer-term evidence suggests antidepressants differ in how well they keep symptoms improved, not just in how quickly they work. Ask your physician how long-term response and tolerability should factor into your treatment plan.

Further reading

For broader context on treatment options, explore our Mental Health coverage.

Live Poll

Would you trust a doctor's antidepressant choice based on long-term research?